Compare Cassava Sciences Inc (FLNA) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Invesco S&P 500 Low Volatility ETF — how do they compare? Cassava Sciences Inc trades at $1.08 (market cap $53.14M), while Invesco S&P 500 Low Volatility ETF trades at $76.62. The key difference: Invesco S&P 500 Low Volatility ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.
| FLNA | SPLV | |
|---|---|---|
Market Cap | $53.14M | — |
Sector | Health | — |
52-Week High | $4.64 | $77.45 |
52-Week Low | $1.09 | $70.30 |
Enterprise Value | -$33.43M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
The Invesco S&P 500 Low Volatility ETF (SPLV) trades at $76.58, up 0.88% on the day, with a bullish technical signal from moving averages. The ETF provides exposure to 100 large-cap US stocks selected for their low historical volatility, offering a defensive tilt. Recent news highlights its role as a portfolio diversifier amid tech sell-offs and geopolitical tensions, with a scheduled dividend of $0.14 per share in June 2026.
SPLV offers a defensive equity strategy for investors seeking lower volatility than the broader market. The outlook is supported by its historical resilience during downturns, but its performance is inherently tied to market conditions that favor low-volatility factors. Key risks include underperformance during strong bull markets and the quarterly reconstitution of its underlying index.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
